Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
Charles River Laboratories International Inc (NYSE: CRL) closed the day trading at $150.33 down -10.25% from the previous closing price of $167.49. In other words, the price has decreased by -$10.25 from its previous closing price. On the day, 2.24 million shares were traded. CRL stock price reached its highest trading level at $162.72 during the session, while it also had its lowest trading level at $150.28.
Ratios:
For a better understanding of CRL, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 40.39 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.76. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.36. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.83.
On May 23, 2025, Redburn Atlantic Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $182.
TD Cowen Upgraded its Hold to Buy on May 14, 2025, while the target price for the stock was maintained at $179.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 21 ’25 when WALLMAN RICHARD F bought 8,500 shares for $150.00 per share.
WALLMAN RICHARD F bought 4,000 shares of CRL for $550,000 on Jun 23 ’25. On May 15 ’25, another insider, MASSARO GEORGE, who serves as the Director of the company, sold 140 shares for $137.57 each. As a result, the insider received 19,260 and left with 5,575 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRL now has a Market Capitalization of 7398370816 and an Enterprise Value of 11033815040. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.83 while its Price-to-Book (P/B) ratio in mrq is 2.21. Its current Enterprise Value per Revenue stands at 2.743 whereas that against EBITDA is 12.415.
Stock Price History:
The Beta on a monthly basis for CRL is 1.47, which has changed by -0.2555341 over the last 52 weeks, in comparison to a change of 0.19283521 over the same period for the S&P500. Over the past 52 weeks, CRL has reached a high of $234.90, while it has fallen to a 52-week low of $91.86. The 50-Day Moving Average of the stock is -2.67%, while the 200-Day Moving Average is calculated to be -7.75%.
Shares Statistics:
Over the past 3-months, CRL traded about 990.27K shares per day on average, while over the past 10 days, CRL traded about 1035380 shares per day. A total of 49.21M shares are outstanding, with a floating share count of 48.56M. Insiders hold about 1.12% of the company’s shares, while institutions hold 109.80% stake in the company. Shares short for CRL as of 1752537600 were 2315410 with a Short Ratio of 2.34, compared to 1749772800 on 2605883. Therefore, it implies a Short% of Shares Outstanding of 2315410 and a Short% of Float of 5.42.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Charles River Laboratories International Inc (CRL) is currently under the scrutiny of 7.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $2.41, with high estimates of $2.54 and low estimates of $2.24.
Analysts are recommending an EPS of between $10.46 and $9.79 for the fiscal current year, implying an average EPS of $10.14. EPS for the following year is $10.51, with 16.0 analysts recommending between $11.28 and $9.6.
Revenue Estimates
9 analysts predict $975.03M in revenue for the current quarter. It ranges from a high estimate of $1.01B to a low estimate of $954.6M. As of the current estimate, Charles River Laboratories International Inc’s year-ago sales were $1.01BFor the next quarter, 9 analysts are estimating revenue of $977.12M. There is a high estimate of $1.01B for the next quarter, whereas the lowest estimate is $964.26M.
A total of 10 analysts have provided revenue estimates for CRL’s current fiscal year. The highest revenue estimate was $4.03B, while the lowest revenue estimate was $3.89B, resulting in an average revenue estimate of $3.95B. In the same quarter a year ago, actual revenue was $4.05BBased on 14 analysts’ estimates, the company’s revenue will be $4.02B in the next fiscal year. The high estimate is $4.13B and the low estimate is $3.79B.
